You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Claims for Patent: 9,504,699

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,504,699

Title:	Delayed-release glucocorticoid treatment of rheumatoid disease
Abstract:	The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.
Inventor(s):	Schaeffler; Achim (Beerfelden, DE)
Assignee:	HZNP Limited (Hamilton, BM)
Application Number:	14/563,000
Patent Claims:	1. A method for the treatment of a patient suffering from signs and symptoms of an underlying rheumatic disease who had previously been treated with an oral immediate release dosage form of a glucocorticoid, which method comprises administering daily, at or before bedtime, for at least about two weeks an effective amount of prednisone contained in a delayed-release dosage form to said patient who had previously been treated with an oral immediate release dosage form of a glucocorticoid, wherein the delayed release dosage form is a tablet or a capsule. 2. The method of claim 1, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about four weeks. 3. The method of claim 2, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about eight weeks. 4. The method of claim 3, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form one for at least about twelve weeks. 5. The method of claim 4, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about twelve months. 6. The method of claim 1, wherein the rheumatic disease is rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatica. 7. The method of claim 1, wherein the delayed-release dosage form has a lag time of from about 3 hours to about 5 hours after administration. 8. The method of claim 1, wherein the delayed-release dosage form has a dissolution time of equal to or less than about 2 hours after the lag time is reached. 9. The method of claim 1, wherein the delayed-release dosage form has a drug release behaviour which is independent of pH.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.